Is constantly trying to figure out what the h#ll he is doing.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I almost hate to ask - as I refuse to follow AdamF on principle. But does anybody have a link to what that butthead wrote up about CVM and the ASCO meeting?
The ASCO 2022 poster for the Phase III trial results.
https://cel-sci.com/wp-content/uploads/2022/06/CEL-SCI-ASCO-2022-Poster-6032-June-6-Head-and-Neck-Cancer-1.pdf
I don't see a link to the one with the modeling algorithm.
I didn't delete those messages, although I could have done so. The system admins beat me to removing them.
Posts about or focused on other posters are one of the potential TOS violations that can get posts removed.
Yep,... A very precipitous drop. A really big what - like 500K trade in there as well.
Ampio Pharmaceuticals CEO Mike Martino Issues Letter to Stockholders
4:30 PM ET 6/2/22 | Dow Jones
ENGLEWOOD, Colo., June 2, 2022 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunomodulatory therapies for the treatment of pain resulting from osteoarthritis in the knee and potentially other articular joints, today released the following letter to stockholders from its Chief Executive Officer, Mike Martino.
Dear Fellow Stockholders,
On behalf of the board and management team, we appreciate the support and patience you have demonstrated over the last several weeks. The purpose of this letter is to answer the questions we can currently answer in the context of our previously announced process to evaluate strategic alternatives for Ampion(TM) and Ampio. It is important to note that we won't comment about the earlier announcements regarding personnel and governance changes. Additionally, this letter does not address the previously announced internal investigation, which is ongoing. We know these questions are top of mind for many investors, but we simply cannot speak about these issues at the present time.
I would like to start with AP-013, a randomized, saline-controlled, double-blind Phase 3 clinical study evaluating the efficacy of an intra-articular injection of Ampion(TM) in adults with pain due to severe osteoarthritis of the knee ("AP-013") and key steps we are taking to determine if it's appropriate to conduct an additional trial or set of trials. Let's start with the evidence we have reviewed from the trial results. Compared to baseline, Ampion-treated patients have shown clear evidence of reduction of pain and improvement in function as early as 2 weeks after dosing which lasted up to 24 weeks. However, the saline control that Ampion was evaluated against in AP-013 and earlier trials is an active control, not a placebo, and it showed benefit as well. As a result, the pre-specified intent-to-treat population analysis of AP-013 did not demonstrate a statistical benefit of Ampion when compared with saline on either pain or function over the 12-week efficacy analysis period. According to the agreed upon Special Protocol Assessment ("SPA") with the United States Food and Drug Administration ("FDA"), the AP-013 trial was required to demonstrate a statistical benefit of Ampion when compared with saline on both endpoints (i.e., pain and function).
Additionally, while the per-protocol analysis of AP-013 was initially encouraging, additional scrutiny of the data and methodology supporting the analysis showed that the per protocol analysis was flawed. In particular, that analysis disproportionately captured the best performers from the Ampion-treated population and the worst performers from the saline-treated population. This is purely the result of applying the major protocol deviation criteria included in the protocol. However, the resulting per protocol analysis cannot be used as a basis for submission of a biologics license application to FDA.
On the positive side, we have reconfirmed that the AP-003-A trial, which reflected an enrollment of 329 symptomatic moderate-severe osteoarthritis of the knee (OAK) patients, demonstrated a statistically significant decrease in pain at 12 weeks compared to saline (p=0.004). Additionally, Key Opinion Leaders we've consulted with remain optimistic about the potential for designing a clinical trial that can show a beneficial effect, but there are obviously challenges that will need to be evaluated and weighed against other potential strategies available for Ampion and Ampio as a company.
We now have data in more than 1,500 Ampion-treated participants, and a like number of saline-treated patients, and we are merging all the data into a meta-analysis to inform potential designs for any future trial that we may conduct. We believe this will increase the probability of designing a trial in which Ampion may achieve a statistically significant benefit, and all design elements of the trial are currently under review, including endpoints, the statistical analysis plan, inclusion/exclusion criteria, improved subjective methods for evaluating pain at baseline, and trial monitoring and reporting elements.
It is also important to remember that AP-013 was intended as a confirmatory trial to AP-003-A. If our trial design is substantially different from our previous trials, we may be required to perform two pivotal trials.
Additionally, the trial may need to be conducted under a Special Protocol Assessment (SPA) with FDA, with an agreed to statistical analysis plan. Until we gain more regulatory clarity, partnership discussions are understandably on hold. However, several potential partners have indicated their willingness to re-engage once we gain that clarity. The potential need for two pivotal trials, the regulatory pathway, and partner interest are among the top factors that we are considering as we evaluate our strategic alternatives.
Moving on to the COVID-19 program. As reported in May, we have found no clinically meaningful treatment effect signals from the Company's three COVID-19 clinical trials; AP-017, AP-018 and AP-019. In other words, we were unable to detect a statistically significant difference between Ampion and placebo for the primary endpoints of the trials, which were mortality and time to mechanical ventilation. Signs of potential Ampion benefit were seen in a few prespecified secondary endpoints. However, most of the secondary endpoints did not show a treatment benefit.
How did we go from "positive results" for inhaled Ampion in the 40-patient AP-014 trial to "no signal" in these trials? In general, small exploratory studies may show a large treatment effect because of the small denominator and should always be viewed as hypothesis generating rather than definitive. Historically, across all drug development categories, only a minority of phase 2 trials can be confirmed in larger phase 3 trials. This is the reason why FDA requires two successful pivotal phase 3 trials. Specific to Ampion, the AP-019 trial enrolled 129 participants and could not show a beneficial effect of Ampion compared with placebo as only 3 deaths or progression to respiratory failure occurred (the original primary endpoint). The AP-017 trial which studied intravenous Ampion compared with placebo enrolled only 35 participants and had a very slow enrollment rate. We determined that the evolving treatment landscape combined with the reduced incidence and severity of COVID had significantly curtailed our ability to enroll the required 200 subjects and, as such, the trial was closed because of the projected time to completion and financial commitment. AP-018 was a small Phase 1 study to document safety that enrolled 32 patients and failed to show a benefit.
Given these results and the changing Covid treatment landscape, we believe it would be an unwise use of investor funds to continue the COVID-19 program at this time. As a reminder, AP-017 and AP-019 were initiated on the premise they might support an Emergency Medical Use Authorization (EMUA) in what was then a bleak landscape for Covid treatments. However, several treatments have recently been approved for the treatment of COVID-19, including antibodies that inactivate the SARS-cov-2 virus that causes Covid, as well as drugs that prevent viral replication, and corticosteroids that have demonstrated a reduction in the severity of the disease. Additionally, the prevalence of vaccines and multi-shot vaccination protocols and the diminishing severity of emerging variants of Covid-19, such as Omicron, have all converged to confer immunity and reduce the number of ICU patients requiring respiratory support. These developments make Covid prevention and treatment a very crowded competitive space in which Ampion simply hasn't demonstrated sufficient benefits to be competitive.
I would like to highlight the following positive takeaways which should not be minimized. We now know that nebulized (inhaled) Ampion has an excellent safety profile, which can potentially open up additional target indications that involve lung inflammation which are potentially more promising than COVID-19. Additionally, we have been issued four significant patents in the space. If, how or when we continue to pursue development of Ampion for treatment of respiratory inflammation has yet to be determined; although, I can say it is not a near term project or priority.
Turning briefly to the financials, as of March 31, 2022, we had $28.8 million of cash and cash equivalents. We will be burning $1.2-$1.3 million per month through September 2022 primarily due to required close-out costs for all prior trials, both OAK and COVID-19 related. After September 2022, we project a burn rate of approximately $1.0 million per month, which we will seek to trim further (though as previously mentioned, Ampio is a very lean organization). Based on our current cash position and projection of operating expenses and capital expenditures, we believe we will have sufficient liquidity to fund operations into the second half of 2023. However, this estimate does not include the cost of funding new trials or programs or any other strategic alternatives nor any expense reductions. Rest assured we will be taking a very hard look at any additional expenses prior to committing to them.
To conclude, we are working diligently to evaluate all options to deliver value for stockholders, including but not limited to, additional trials for Ampion, evaluating other opportunities in our pipeline, leveraging our bioprocessing capability, and considering business development opportunities. We look forward to providing you future updates as our evaluation of these alternatives continues.
About Ampio Pharmaceuticals, Inc.
Ampio Pharmaceuticals, Inc. is a biopharmaceutical company primarily focused on the advancement of immunology-based therapies for the potential treatment of multiple inflammatory conditions (e.g., osteoarthritis of the knee (OAK) and other articular joints). Ampio's lead drug is Ampion(TM).
Forward-Looking Statements
(MORE TO FOLLOW) Dow Jones Newswires
June 02, 2022 16:30 ET (20:30 GMT)
Somebody is apparently feeling optimistic about how the data are going to be received at the ASCO meeting this weekend? Up almost 12% on the day now.
Up about 18% on the day as of now and looks like $4.12.
Interesting article - Thanks for sharing.
I'm a bit fuzzy on the author's interpretation on the Tumor Response section. He/she may be over-interpreting the pre-surgery responders a bit.
I don't see any indication in the abstract itself that suggests that some of the responders had complete disappearance of tumors. If that is true, even better of course. Just a simple shrinkage of tumors with 3 weeks of Multikine is definitely still a big benefit.
I especially liked the sections of the article where the author discusses the potential application of Multikine to other solid tumor types. Once Multikine is approved (assuming a successful BLA and review) for H&N cancers, it would be relatively easy (as the author points out) to set up some Phase II type tests for some of the types of breast cancer or maybe bone cancers with similar problems in treatment. If disfiguring surgery can be avoided, or if tumor masses can be shrunk before surgery, then the potential applications of Multikine could be quite extensive and lucrative.
Thanks for posting these. Nothing that we didn't already generally know in the 2nd Abstract.
First Abstract covers the predictive model for typing the cancer risk groups. It's not a perfect predictor, but it's apparently pretty good.
From the Abstract:
Conclusions:
The algorithm provided near perfect (99.9%) ITT population coverage, achieved near 75% overall accuracy, with 91.8% accurate predictive value for the low-risk group demonstrating significant OS. Thus, risk group can be inferred at screening consistent with clinical practice and NCCN Guidelines. The algorithm can be used to help identify low risk SCCHN patients at entry to receive neoadjuvant immunotherapy before surgery.
I expect no meaningful and lasting bump in share prices for CVM until we see the FDA application actually PRed - as in - meetings scheduled and application materials actually submitted.
We might see some bump if a peer-reviewed manuscript is accepted, and of course if the company makes some announcement about a partnership or licensing agreement with a big Pharma fish - that'll mean something.
Meeting abstracts will have - at best - a short bump that won't hold.
CVM's share prices are still loitering around the $3-mark (up a bit, down a bit, rinse & repeat) despite the abstracts being released this week for one primary reason:
The Abstracts being made public is kind of meaningless in the long-run for CVM. Period.
The only medium to long-term drivers that are going to be important are those showing stepwise progress towards getting the BLA application completed and submitted to the FDA, getting the drug accepted by the FDA, and getting some revenue flowing from the market for Multikine.
Assuming the data in this Phase III hold up to what was seen for the subset of patients from the Phase II that the company is now targeting - 2023 could be a big year. The end of 2022 could be kind of fun as well.
Yep 2022 is a busy year for CVM. 2023 should bring things to a head.
The upswing here makes zero sense. Especially with pretty much everything else in the broader market tanking all week.
I've been buying small lots of shares steadily every month or so ever since the prices dropped under about $5 in my trading account and in my Roth. I'm good!
I'll lose money at 70-80 cents - but not nearly as much as I would at 20 cents or less. I'll take the loss at that point and take whatever's left and head on to the next thing with it.
Oh well - that's why you should never invest with money you can't afford to lose.
Yeah,.... That ain't good.
True - most of biotech has been hammered since last year. That could be at least part of the explanation.
Admittedly I had been using the lowered share prices to judicially add to my stashes of things like CVM and CFRX that have treatments that are either in Phase III or have recently finished a Phase III.
I was doing the same with AMPE - but their management did some really dumb things recently with Phase III data, got their study deep-sixed by FDA review, and although I have not sold my shares in that, I have not been adding any.
Nice move upward today. Anybody seen any news other than the most recent financial report?
Nothing appears to have changed on the ClinicalTrials.gov site.
I am mostly curious as to when they might have their finalized Phase I data ready to share or try and publish, and what their plans going forward are going to be to get a Phase II started.
I've been following this company for a lot of years. I got rid of all my old shares several years ago before they did a big dilution and ate the loss, but bought back in a small number again a couple of years back when it looked like the Phase I was going along well.
I'm guessing that their cash outflow dropped that 98% because they aren't paying for an active Phase I any longer, but the bump in revenue from their subsidiaries was nice. It won't be enough to pay for a Phase II, but it does speak well for keeping the lights on and the lab running in the meantime.
NanoViricides stock rises on starting drug screening program to fight severe hepatitis in kids
May 16, 2022 9:26 AM ET
NanoViricides, Inc. (NNVC)
By: Ravikash, SA News Editor
NanoViricides (NYSE:NNVC) stock rose premarket on May 16 after the company said it began drug development to fight recent cases of severe pediatric hepatitis.
The company said it began a program to screen its library of broad-spectrum antiviral nanoviricides against human Adenovirus 41 Type F (hAd41-F), believed to be linked with the occurrence of severe hepatitis syndrome in some children, causing liver transplants and deaths.
NanoViricides (NNVC) said it believes it can develop a drug candidate against hAd41-F in a relatively short time, if any existing pipeline candidate or other nanoviricide candidates in its library are found to be effective.
The Shelton, Conn.-based company is developing an antiviral assay for testing these drug candidates against hAd41-F infection in cell cultures in its own BSL2 Virology facility.
NanoViricides (NNVC), however, noted that its top priority remains to start human clinical trials of its COVID-19 drug candidate NV-CoV-2.
The company expects filing of a clinical trial application for COVID-19 to take place soon, but noted that the timelines are outside its control.
NNVC +12.19% to $1.45 premarket May 16
Well - at least they mention this:
This periodic cycling between $2s and $3s is going to keep right on happening until there is actual news.
Thanks for the information Dr. Johnny.
Do you have a link for where this letter is posted? I didn't see it on the corporate webpage when I checked a bit ago.
Yeah - there may still be some shorter-term upside (up from this low point anyway) if the COVID data show anything promising. I'm not selling what I am holding either for the time being, unless I take some profit elsewhere and decide to sell for the tax loss break before the end of 2022.
I've got another biomed (CVM) that 'could' take off this year, and if I start cashing some of that out, the tax-losses from AMPE could be useful to cut the tax burden. I won't take my eyes off of AMPE either, and if I do sell, it'll be with the idea that I buy back into incrementally sometime during 2023.
Ditto here - I haven't seen anything else that supports this claim. I was only speculating whether it could have been done, and if so, how it might come about.
I'll believe it when I see it from a more verifiable source.
Is that possible? Could be - depending on their justifications for any changes, and what adjustments they might have had to the stats or data.
I personally only have fairly basic statistics skills - as I don't generally do any experiments with complicated statistical designs or noisy data sets. I would have to see what they had done to their data and their justifications for having done so. And even then I would probably have to have an actual statistician explain it to me. My ex probably could do it - she makes her living as a biostatistician and project manager working for NIH.
Yeah - that was amazingly dumb.
No argument from me on this point. I won't believe it until it actually happens and is documented somewhere reputable.
NanoViricides provides update on potential COVID drug NV-CoV-2
https://seekingalpha.com/news/3826079-nanoviricides-provides-update-on-potential-covid-drug-nv-cov-2
Good news for a change? Was on my ETrade dashboard this morning:
NanoViricides Provides Update On NV-CoV-2 Coronavirus Drug Candidate Program
6:45 AM ET 4/25/22 | Dow Jones
SHELTON, CT / ACCESSWIRE / April 25, 2022 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform is providing an update on its clinical-trial ready Coronavirus Oral and Injectable Drug Programs.
NanoViricides is close to completing an Investigators Medicinal Product Dossier that is required as part of the clinical trial application for its lead drug candidate for the treatment of COVID-19, NV-CoV-2. Simultaneously the Company is rapidly getting its manufacturing systems set up for producing the drug products for the clinical trials.
The Company believes it has sufficient funds for the Phase I/II human clinical trials of this COVID-19 drug candidate.
The NV-CoV-2 drug candidate is designed to act by a novel mechanism of action, that the Company calls "Re-infection Blocker". NV-CoV-2 has been found to have pan-coronavirus activity, which suggests that it should continue to work against emerging variants of SARS-CoV-2, the pandemic coronavirus.
It will be possible to combine NV-CoV-2 with other treatments for improved effect, if necessary, because the mechanism of action of NV-CoV-2 is orthogonal to the mechanisms of most if not all other known COVID-19 drugs.
As new variants of SARS-CoV-2 have evolved over time, their transmissibility has increased. The new Omicron BA.2 variant and its descendants (such as XE) are almost as contagious as the measles virus, one of the most contagious viruses known, according to scientists (https://news.yahoo.com/omicron-variants-explained-everything-know-220059889.html).
Scientists have repeatedly warned that a more severe variant that retains this high transmissibility and escapes available vaccines and antibodies could emerge anywhere, given the wide spread of the global pandemic. At present, a fourth booster shot is only expected to protect against new infection for about eight weeks, although protection against severe disease is likely much longer lasting, according to an Israeli study (https://www.nejm.org/doi/pdf/10.1056/NEJMoa2201570?articleTools=true).
A further danger lurking out there is that, a new variant could emerge in vaccinated persons that actually uses the vaccine-induced antibodies to hitch a ride on them and cause more severe infections, known as "Antibody-Dependent Enhanced" (ADE) Effect. SARS-CoV-1 and MERS-CoV are known to be capable of generating ADE mutants, and thus this possibility cannot be ignored for their close cousin, SARS-CoV-2, the current pandemic virus, according to scientists (https://www.statnews.com/2022/02/16/coronaviruses-are-clever- evolutionary-scenarios-for-the-future-of-sars-cov-2/).
Thus, we need to be prepared with an effective broad-spectrum, pan-coronavirus drug. Such a drug would continue to work against the emerging virus variants.
The Company believes NV-CoV-2 is exactly the drug that the world needs today, based on pre-clinical studies. Further, NV-CoV-2, based on its strong safety profile, is not expected to have any restrictions on its use such as those that have dogged currently available oral therapies, namely Paxlovid (Pfizer) and Molnupiravir (Merck).
NV-CoV-2 was found to be a broad-spectrum, pan-coronavirus drug candidate in pre-clinical studies. Escape of virus due to variants is expected to be highly unlikely because of this broad-spectrum antiviral activity of NV-CoV-2. NV-CoV-2 was also found to be significantly more effective than remdesivir in animal studies of lethal direct lung coronavirus infection that simulates the SARS-CoV-2 disease. Remdesivir is the only fully approved drug for the treatment of SARS-CoV-2 (COVID-19) at present, and is highly effective in cell culture studies, but has limited effectiveness in clinical studies.
Moreover, the mechanism of action of NV-CoV-2 is orthogonal to that of Paxlovid(TM) (Pfizer). Thus the two therapies can be given together for synergistic effect.
NV-CoV-2 has been found to be extremely safe and non-mutagenic in GLP and Non-GLP Safety/Toxicology studies. NV-CoV-2 has demonstrated good oral bioavailability in animal studies. The Company believes that an effective oral drug to treat COVID-19 remains an unmet medical need.
The Company has developed "Oral Gummies" formulation of NV-CoV-2 successfully. Oral gummies are expected to be more acceptable to children and older patients because of slow dissolution in the mouth and palatability than oral pills that may be difficult to swallow.
The Company has completed formulation and stability studies for the oral and injectable dosage forms of NV-CoV-2.
The Company is currently conducting manufacturing scale-up of the formulated materials into drug products. The manufacturing scale-up for the active ingredient, called NV-387, is now completed as required for initiating human clinical trials.
The NV-CoV-2 Oral Gummies will be made available in blister packs. The Company has devised a novel production method for this novel presentation of an oral antiviral drug. The Company has successfully designed the blister packs and the equipment for making the blister packs. The Company has devised custom equipment for filling and sealing the blister packs based on our novel production method.
The NV-CoV-2 Oral Syrup will be made available in sealed plastic bottles for the clinical trial supply. The Company intends to move to single-use dose-packets of the oral syrup once the dosage can be finalized based on clinical trials.
Bench scale equipment for production of the NV-CoV-2 Blister Packs as well as NV-CoV-2 Oral Syrup that is sufficient for the Phase I human clinical trials is being commissioned already. This equipment will be used to speed up the entry into Phase I/IIa clinical trials. Automated, larger scale custom equipment is on order. The automated equipment is expected to be set up in working condition for Phase II human clinical trials.
The Company has also developed NV-CoV-2 formulations for injection, infusion and direct lung inhalation using a simple mouthpiece. The inhalation drug formulation is expected to benefit severely ill patients as it enables delivering much higher levels of drug (than infusion or oral dosing) directly to the lung tissue thereby helping to minimize the lung viral load and lung damage, for rapid recovery of hospitalized patients.
NanoViricides is one of a few biopharma companies that has its own cGMP-compliant manufacturing facility. The Company intends to produce its drugs for clinical trials in this facility. The Company has the capability to produce sufficient drugs for about 1,000-5,000 patients in a single batch of production, depending upon the drug and the dosage. This production capacity is anticipated to be sufficient for the Phase I and Phase II human clinical trials for our anti-coronavirus drug in development, as well as for the anticipated clinical trials of NV-HHV-101 skin cream for the treatment of shingles.
The Company has previously completed IND-enabling studies for another drug candidate, NV-HHV-101 for the treatment of shingles rash caused by reactivation of the chickenpox virus (aka varicella-zoster virus, VZV). The Company plans on further developing the shingles drug candidate into human clinical trials after clinical trials of our COVID-19 drug candidate. The Company has additional drugs in its pipeline at various pre-clinical stages that it plans to develop towards regulatory approvals after the COVID-19 and Shingles drug clinical trials.
About NanoViricides
NanoViricides, Inc. (the "Company")(www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide(R) class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. Our lead drug candidate is NV-HHV-101 with its first indication as dermal topical cream for the treatment of shingles rash. In addition, we are developing a clinical candidate for the treatment of COVID-19 disease caused by SARS-CoV-2 coronavirus. The Company cannot project an exact date for filing an IND for this drug because of its dependence on a number of external collaborators and consultants.
The Company is now working on tasks for completing an IND application. The Company is currently pursuing two separate drug candidates for the treatment of COVID-19 patients. NV-CoV-2 is our nanoviricide drug candidate that does not encapsulate remdesivir. NV-CoV-2-R is our other drug candidate that is made up of NV-CoV-2 with remdesivir encapsulated in it. The Company believes that since remdesivir is already US FDA approved, our drug candidate encapsulating remdesivir is likely to be an approvable drug, if safety is comparable. Remdesivir is developed by Gilead. The Company has developed both of its own drug candidates NV-CoV-2 and NV-CoV-2-R independently.
The Company intends to re-engage into an IND application to the US FDA for NV-HHV-101 drug candidate for the treatment of shingles once its COVID-19 project moves into clinical trials, based on resources availability. The NV-HHV-101 program was slowed down because of the effects of recent COVID-19 restrictions, and re-prioritization for COVID-19 drug development work.
(MORE TO FOLLOW) Dow Jones Newswires
April 25, 2022 06:45 ET (10:45 GMT)
No argument.
Correct - Abstracts for meeting presentations and meeting posters generally are not subject to a scientific review before being accepted.
Of those posters and meeting presentation abstracts I have written up for professional meetings the only things that are generally looked at are formatting, length constraints, and whether (or not) the topic (in general) is appropriate for that meeting. Then the submitter pays a (usually small) fee to the conference organizers.
Essentially, the 'peer review' for these things comes when the meeting is active, and when those viewing the poster or presentation can question the presenter.
We shall see - won't we.
Interesting take on the idea Q. I've been expecting some kind of either buyout offer or partnership offer from some big pharma once the peer review was done, but not until after the BLA was cooking with the FDA.
That's kind of my plan with the CVM shares I have in my non-Roth account.
Some time after the one year + one day timeline after they were bought - assuming we get good news in the Fall and Winter of 2022 - I will start selling those shares in small lots. I'll deal with the 20% Fed long-term gains, and unfortunately my State of MD will pull in another 15% capital gains because I have >$40K actual income. But if this swings up over $100/share, my long-term cost average in that account is about $5-6/share.
I'll gladly start taking some profits and while I will grumble about the taxes, I won't be grumbling too much.
Yep. That's about the size of it. That is AF's MO in a nutshell.
I guess we will see in a couple of days if there "is" anything to be PRed on Thursday. In the meantime, the price drop today after that news and after yesterday's run-up is hardly a surprise.
Agreed. Geert is many things - but he's not stupid. And anything that Adam F. publishes has to be viewed as slanted, self-serving, and most likely a half-truth.